Bone marrow transplant for multiple myeloma

Research output: Contribution to journalReview articlepeer-review


Marrow transplantation for multiple myeloma is now a well-established therapeutic intervention. Allogeneic transplant has the advantage that it is potentially curative by virtue of graft versus myeloma effect. Unfortunately, the up-front mortality is approximately 40% in the first year. Autologous transplantation can be accomplished with a much lower risk of approximately 2-4%. Unfortunately, autologous transplantation is not curative for this disease and the median prolongation of survival is approximately 15 months. The ultimate role of transplantation in the overall management of younger patients with multiple myeloma remains a subject for future research.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalCancer Research Therapy and Control
Issue number3-4
StatePublished - 1999


  • Bone marrow transplantation
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Bone marrow transplant for multiple myeloma'. Together they form a unique fingerprint.

Cite this